EuBiologics Co., Ltd. (KOSDAQ: 206650)
South Korea
· Delayed Price · Currency is KRW
10,360
+390 (3.91%)
Sep 11, 2024, 11:08 AM KST
EuBiologics Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
Sep '24 Sep 10, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Market Capitalization | 383,610 | 418,137 | 324,359 | 1,271,414 | 655,399 |
Market Cap Growth | 28.91% | 28.91% | -74.49% | 93.99% | - |
Enterprise Value | 380,342 | 418,132 | 320,550 | 1,239,111 | - |
Last Close Price | 10500.00 | 11470.00 | 8900.00 | 35050.00 | 21300.00 |
PE Ratio | - | -30.10 | -294.83 | -45.05 | -9.92 |
PS Ratio | 5.52 | 6.03 | 5.85 | 32.28 | 23.00 |
PB Ratio | 3.44 | 3.99 | 2.72 | 10.84 | 6.77 |
P/FCF Ratio | 19.66 | 21.43 | -123.50 | -89.56 | -102.88 |
P/OCF Ratio | 15.81 | 15.81 | 50.37 | -167.25 | 395.02 |
EV/Sales Ratio | 5.48 | 6.03 | 5.78 | 31.46 | - |
EV/EBITDA Ratio | 23.26 | 24.79 | 77.93 | -1861.89 | - |
EV/EBIT Ratio | 52.92 | 54.31 | -85.06 | -171.40 | - |
EV/FCF Ratio | 19.49 | 21.43 | -122.05 | -87.28 | - |
Debt / Equity Ratio | 0.14 | 0.14 | 0.13 | 0.13 | 0.23 |
Debt / EBITDA Ratio | 0.88 | 0.88 | 3.81 | - | - |
Debt / FCF Ratio | 0.76 | 0.76 | -5.96 | -1.09 | -3.54 |
Asset Turnover | 0.44 | 0.44 | 0.35 | 0.26 | - |
Inventory Turnover | 2.26 | 2.26 | 1.95 | 2.01 | - |
Quick Ratio | 0.77 | 0.77 | 0.59 | 1.99 | 1.65 |
Current Ratio | 1.63 | 1.63 | 1.67 | 3.11 | 2.03 |
Return on Equity (ROE) | -13.70% | -13.70% | -2.90% | -26.17% | - |
Return on Assets (ROA) | 3.07% | 3.07% | -1.51% | -2.95% | - |
Return on Capital (ROIC) | 3.78% | 3.78% | -1.76% | -3.58% | - |
Earnings Yield | -3.63% | -3.32% | -0.34% | -2.17% | -9.18% |
FCF Yield | 5.09% | 4.67% | -0.81% | -1.12% | -0.97% |
Buyback Yield / Dilution | -0.13% | -0.13% | -2.68% | -26.53% | - |
Total Shareholder Return | -0.13% | -0.13% | -2.68% | -26.53% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.